Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BESREMi safely and effectively. See full prescribing information for BESREMi.BESREMi (ropeginterferon alfa-2b-njft) injection, for subcutaneous use Initial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
BESREMi is indicated for the treatment of adults with essential thrombocythemia. BESREMi is indicated for the treatment of adults with polycythemia vera.
- generic_name
- ropeginterferon alfa-2b
- product_names
- ROPEGINTERFERON ALFA-2B
- ndc
- 73536-500, 73536-500-01, 73536-511, 73536-511-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en